Answers are grounded in this paper and cite their sources.
Financial analysis identifies key pricing for BPaL(M) to enhance MDR/RR-TB treatment in China, suggesting policy implications.
What is already known about this topic?: The BPaL(M) regimen is a World Health Organization (WHO)-endorsed, all-oral, shorter treatment for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) recently approved in China; however, its large-scale implementation depends on affordability and sustainability within the national health insurance system. What is added by this report?: This study identifies 26,000 Chinese Yuan (CNY) per course as an approximate break-even pretomanid price for health insurance reimbursement in China. Lower prices can generate savings for both insurers and patients. What are the implications for public health practice?: Pretomanid price negotiations should be combined with reimbursement and financial protection policies to support equitable scale-up of BPaL(M).
No takes yet. Share an insight, caveat, or question.
Ren et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: